Novel obesity treatment company EnteroMedics (NASDAQ:ETRM) that has survived a close brush with disaster recorded revenue for the first time since it was incorporated nearly eight years ago. On Tuesday, the company reported revenue of about $123,000 in the first quarter of the year that were garnered from the sale of its implantable neuromodulation system — Maestro […]
Let’s do it again. EnteroMedics Inc., based in Roseville, Minnesota, said Monday that the Food and Drug Administration has approved a new clinical trial for its Maestro anti-obesity device that uses electricity to suppress hunger. The news represents a major victory for EnteroMedics whose previous study ended in failure. Last October, initial results from the […]
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Someday, in the not-so-distant future, EnteroMedics Inc. officials might look back at late 2009 and laugh. Or cry. That ultimately depends on whether the Food and Drug Administration ultimately approves or rejects the company’s groundbreaking Maestro device. Approval means enormous financial success, the only implantable neurostimulation device in the United States designed to treat obesity. […]
EnteroMedics and Leptos are both developing a device that uses electricity to treat obesity. But that's where the similarities end, EnteroMedics CEO Mark Knudson told me in a quick phone call.
EnteroMedics is dangling precariously off a cliff. Last fall, initial results from its Empower clinical study failed to meet the company's goals.